APR Applied Pharma Research s.a. and Labtec GmbH Enter Into Exclusive Licensing Agreement With Ferrer Internacional for the Registration and Marketing of Donepezil Oral Dispersible Film10/01/10 - APR and its development partner Labtec have entered into an exclusive licensing agreement with the leading European pharmaceutical company Ferrer Internacional (Ferrer) for the promotion, distribution and marketing of Donepezil Oral Dispersible Film (ODF) in Spain, Portugal and Germany. Terms of the deal were not disclosed.
“It is an honor to work with a dedicated and professional company like APR. Donepezil Rapidfilm with its unique delivery system will be part of Ferrer’s CNS portfolio and is in line with our overall aim to bring new treatment alternatives for our patients,” said José Luis Fumanal, Vice President Domestic Operations Pharma of Ferrer. “As Ferrer has a successful track record in licensing collaborations, we are convinced that the current agreement with APR will be the initiation of another long-lasting partnership strengthening our supportive care line for our patients.”
“Market trends are clear,” said Paolo Galfetti, CEO of APR. “The future of many molecules to become off-patent such as Donepezil will be determined by dosage form diversification and patient compliance. ODF certainly is the oral dosage form contributing the most to compliance by ensuring drug delivery while being easy to use without any discomfort for patients and doctors. We are also very pleased that such a reputable company as Ferrer Internacional took the Donepezil ODF opportunity for such key markets in Europe. I would also like to express my appreciation for the great co-operation we had from Bioselenia, our strategic licensing partner, that helped to build the connection between APR and Ferrer Internacional on this deal.”... Labtec's Press Release - Applied Pharma Research's Press Release -
“Market trends are clear,” said Paolo Galfetti, CEO of APR. “The future of many molecules to become off-patent such as Donepezil will be determined by dosage form diversification and patient compliance. ODF certainly is the oral dosage form contributing the most to compliance by ensuring drug delivery while being easy to use without any discomfort for patients and doctors. We are also very pleased that such a reputable company as Ferrer Internacional took the Donepezil ODF opportunity for such key markets in Europe. I would also like to express my appreciation for the great co-operation we had from Bioselenia, our strategic licensing partner, that helped to build the connection between APR and Ferrer Internacional on this deal.”... Labtec's Press Release - Applied Pharma Research's Press Release -
January 20, 2010 – 
